Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $30.25.

A number of research analysts have recently commented on the company. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Citigroup assumed coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating for the company. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th.

Insider Buying and Selling at Bicara Therapeutics

In other news, CFO Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.25, for a total transaction of $54,074.75. Following the transaction, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,652,728.75. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Claire Mazumdar sold 1,596 shares of the business’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20. Following the completion of the sale, the chief executive officer directly owned 339,392 shares in the company, valued at approximately $6,431,478.40. This represents a 0.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 128,769 shares of company stock valued at $2,415,814. 15.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in Bicara Therapeutics during the 1st quarter worth about $248,000. Woodline Partners LP increased its stake in shares of Bicara Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock valued at $4,543,000 after buying an additional 72,998 shares during the period. Geode Capital Management LLC raised its position in shares of Bicara Therapeutics by 36.8% during the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after acquiring an additional 180,833 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its position in shares of Bicara Therapeutics by 119.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock worth $75,000 after acquiring an additional 4,417 shares during the last quarter. Finally, Intech Investment Management LLC lifted its stake in shares of Bicara Therapeutics by 65.3% in the second quarter. Intech Investment Management LLC now owns 27,673 shares of the company’s stock worth $257,000 after acquiring an additional 10,927 shares during the period.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $18.41 on Friday. The company’s 50 day moving average price is $16.98 and its two-hundred day moving average price is $16.27. The firm has a market capitalization of $1.01 billion, a P/E ratio of -8.22 and a beta of -0.78. Bicara Therapeutics has a fifty-two week low of $7.80 and a fifty-two week high of $20.25.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.